Pavan Bhargava, MD
@pavanbhargavamd.bsky.social
Neuroimmunologist with interests in metabolism, gut microbiome, EVs, biomarkers and clinical trials. Associate Professor of Neurology at Johns Hopkins University SOM.
Our latest manuscript that identifies altered proteins in tissue derived extracellular vesilces from normal appearing white matter in MS. Journal of Extracellular Vesicles - Wiley Online Library isevjournals.onlinelibrary.wiley.com/doi/10.1002/...
Extracellular Vesicles From Multiple Sclerosis White Matter Exhibit Synaptic, Mitochondrial, Complement and Ageing‐Related Pathway Dysregulation
This study characterizes extracellular vesicles (EVs) separated from postmortem normal-appearing white matter of multiple sclerosis (MS) and control brains. Proteomic analysis revealed downregulation...
isevjournals.onlinelibrary.wiley.com
November 12, 2025 at 4:50 PM
Our latest manuscript that identifies altered proteins in tissue derived extracellular vesilces from normal appearing white matter in MS. Journal of Extracellular Vesicles - Wiley Online Library isevjournals.onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Pavan Bhargava, MD
For our #flowcytometry peeps, would you like to have a single fix/perm protocol that is optimised for everything? One that preserves fluorophores while allowing simultaneous TF and cytokine staining? How about 100-fold cheaper?
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
currentprotocols.onlinelibrary.wiley.com
September 19, 2025 at 2:39 PM
For our #flowcytometry peeps, would you like to have a single fix/perm protocol that is optimised for everything? One that preserves fluorophores while allowing simultaneous TF and cytokine staining? How about 100-fold cheaper?
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
Our latest manuscript demonstrating the impact of diet on biological aging in people with MS. Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis - Siavoshi - Annals of Neurology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
September 20, 2025 at 7:14 PM
Our latest manuscript demonstrating the impact of diet on biological aging in people with MS. Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis - Siavoshi - Annals of Neurology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Pavan Bhargava, MD
Very pleased to co-write this review with Bruce Cree and Steve Hauser on the future of #multiplesclerosis treatment
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, gui....
onlinelibrary.wiley.com
June 6, 2025 at 2:51 PM
Very pleased to co-write this review with Bruce Cree and Steve Hauser on the future of #multiplesclerosis treatment
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Our latest preprint showing alterations in the proteome of white matter EVs from MS patients compared to controls.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
www.biorxiv.org
June 6, 2025 at 10:12 PM
Our latest preprint showing alterations in the proteome of white matter EVs from MS patients compared to controls.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Reposted by Pavan Bhargava, MD
Worth noting - in this population (median age around 54-55), discontinuation of first-line injectables, teriflunomide, and DMF after 5 years of stability led to substantially higher risk of disease activity. jamanetwork.com/journals/jam...
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis
This randomized clinical trial investigates whether first-line disease-modifying therapy can be safely discontinued in patients with long-term stable multiple sclerosis.
jamanetwork.com
December 10, 2024 at 1:31 PM
Worth noting - in this population (median age around 54-55), discontinuation of first-line injectables, teriflunomide, and DMF after 5 years of stability led to substantially higher risk of disease activity. jamanetwork.com/journals/jam...